Prothix Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Prothix General Information

Description

Developer of bio-pharmaceutical products intended to give protein therapeutics for inflammatory and coagulation disorders. The company's bio-pharmaceuticals are monoclonal antibody products that include humanization and de-immunization of human cells sensitized with anti-human leukocyte antigen antibodies, enabling medical professionals to monitor and treat thromboembolic, inflammatory, and coagulation disorders.

Contact Information

Website
www.prothix.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Warmonderweg 23
  • 2334 AB Leiden
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prothix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 24-Mar-2023 00000 Completed Out of Business
2. Early Stage VC 15-Aug-2011 00000 00000 Completed Generating Revenue
1. Spin-Off 01-Jan-2008 Completed Startup
To view Prothix’s complete valuation and funding history, request access »

Prothix Patents

  • 14

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 9

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Prothix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190106509-A1 Monoclonal antibodies against the active site of factor xi and uses thereof Active 23-Mar-2016 000000000
US-11059905-B2 Monoclonal antibodies against the active site of factor xi and uses thereof Active 23-Mar-2016 000000000 0
EP-3433279-A1 Monoclonal antibodies against the active site of factor xi and uses thereof Pending 23-Mar-2016 000000000
JP-7028471-B2 Monoclonal antibody against the active site of factor xi and its use Active 23-Mar-2016 000000000 0
JP-2019516395-A Monoclonal antibodies against the active site of factor xi and their use Active 23-Mar-2016 C07K16/36 0
To view Prothix’s complete patent history, request access »

Prothix Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Broteio 00000 0000 Drug Discovery
To view Prothix’s complete investments history, request access »

Ready to get started?

Request a free trial